<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033876</url>
  </required_header>
  <id_info>
    <org_study_id>13-004908</org_study_id>
    <nct_id>NCT02033876</nct_id>
  </id_info>
  <brief_title>Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin</brief_title>
  <official_title>Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether bile acids are able to increase insulin sensitivity and
      enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance
      glycemic control. These observations will provide the preliminary data for proposing future
      therapeutic as well as further mechanistic studies of the role of bile acids in the control
      of glycemia in T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Intra-jejunal administration of bile acids improves insulin sensitivity.

      Hypothesis: The bile acid, ursodeoxycholic acid (UDCA) in delayed (ileocolonic)-release
      formulation, stimulates bile acid membrane receptor (TGR-5) and farnesol X (FXR) receptors in
      the ileum and colon, increasing the secretion of Fibroblast growth factor 19 (FGF-19), GLP-1,
      oxyntomodulin (OXM), and Peptide (PYY3-36), improving insulin sensitivity and inducing weight
      loss.

      Aim: To study the effect of an ileocolonic formulation of UDCA on insulin sensitivity,
      postprandial plasma glycemia and incretin levels, gastric emptying and body weight in
      overweight or obese type 2 diabetic subjects on monotherapy with metformin.

      Study design: This is a single center, placebo-controlled, parallel group, single dose
      randomized controlled trial to study the effect of delayed (ileocolonic)-release UDCA 600 mg
      twice daily on insulin sensitivity, gastric emptying of liquids and solids (measured by
      scintigraphy)and weight loss in overweight or obese type 2 diabetic subjects. Participants
      will be receiving monotherapy with metformin. Blood samples will be collected at defined
      times to measure glycemia and the incretin (GLP-1, OXM, PYY3-36) fasting levels and responses
      to the meal.

      Anticipated Results: In comparison with placebo, UDCA will increase insulin sensitivity,
      enhance glycemic control, increase postprandial incretins, and delay gastric emptying (GE) of
      liquids.

      Significance: This study will prove that ileocolonic-release UDCA enhances glycemic control
      in T2DM patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Area Above Basal (AAB) for Glucose</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Mixed meal glucose results are used to calculate the area above basal (AAB) for glucose. The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following an overnight fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Serum glucose measurements taken after 10 hours of fasting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Insulin sensitivity will be calculated by the oral minimal model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying of Liquids (T1/2)</measure>
    <time_frame>post-treatment, approximately 14-17 days</time_frame>
    <description>The time for half of the ingested liquids to leave the stomach. Following a meal with milk labeled with indium In111 diethylenetriaminepentaacetate (0.1 mCi), gastric emptying of liquids was assessed with scintigraphy imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying of Solids (T1/2)</measure>
    <time_frame>post-treatment, approximately 14-17 days</time_frame>
    <description>The time for half of the ingested solids to leave the stomach. Following a meal consisting of two eggs labeled with technetium Tc 99m sulfur colloid (1 mCi) served with 50g of Canadian bacon and one slice of bread gastric emptying of solids was assessed with scintigraphy imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Change in subject's weight, in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Change in subjects BMI, in kilograms per meter squared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FGF-19</measure>
    <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
    <description>Change in fasting fibroblast growth factor (FGF)-19 expression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ursodiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo capsules to be taken twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ursodiol</arm_group_label>
    <other_name>Ursodeoxycholic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Overweight or Obese subjects with BMI&gt; 25 Kg/m2 with Type 2 Diabetes mellitus on Metformin,
        receiving standard of care for Type 2 DM. Otherwise individuals who are not currently on
        treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological,
        neurological, endocrine (other than T2DM) and unstable psychiatric disease.

        Men or women. Women of childbearing potential will have a negative pregnancy test before
        initiation of medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Camilleri, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Pharmacology and Physiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ursodiol</title>
          <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ursodiol</title>
          <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" lower_limit="59" upper_limit="64"/>
                    <measurement group_id="B2" value="57" lower_limit="47.5" upper_limit="64"/>
                    <measurement group_id="B3" value="58.9" lower_limit="47.5" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Area Above Basal (AAB) for Glucose</title>
        <description>Mixed meal glucose results are used to calculate the area above basal (AAB) for glucose. The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following an overnight fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g).</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Area Above Basal (AAB) for Glucose</title>
          <description>Mixed meal glucose results are used to calculate the area above basal (AAB) for glucose. The glycemic index of a food is defined as the incremental area under the two-hour blood glucose response curve (AUC) following an overnight fast and ingestion of a food with a certain quantity of available carbohydrate (usually 50 g).</description>
          <units>mg/dL x min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66458" lower_limit="53501" upper_limit="75478"/>
                    <measurement group_id="O2" value="72566" lower_limit="55654" upper_limit="93006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <description>Serum glucose measurements taken after 10 hours of fasting.</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <description>Serum glucose measurements taken after 10 hours of fasting.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="125.7" upper_limit="158.8"/>
                    <measurement group_id="O2" value="155.7" lower_limit="126.8" upper_limit="166.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Sensitivity</title>
        <description>Insulin sensitivity will be calculated by the oral minimal model.</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity</title>
          <description>Insulin sensitivity will be calculated by the oral minimal model.</description>
          <units>mg/dL x minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19983" lower_limit="15260" upper_limit="28298"/>
                    <measurement group_id="O2" value="19086" lower_limit="13952" upper_limit="24038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying of Liquids (T1/2)</title>
        <description>The time for half of the ingested liquids to leave the stomach. Following a meal with milk labeled with indium In111 diethylenetriaminepentaacetate (0.1 mCi), gastric emptying of liquids was assessed with scintigraphy imaging.</description>
        <time_frame>post-treatment, approximately 14-17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying of Liquids (T1/2)</title>
          <description>The time for half of the ingested liquids to leave the stomach. Following a meal with milk labeled with indium In111 diethylenetriaminepentaacetate (0.1 mCi), gastric emptying of liquids was assessed with scintigraphy imaging.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="50" upper_limit="78.1"/>
                    <measurement group_id="O2" value="63.6" lower_limit="50" upper_limit="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying of Solids (T1/2)</title>
        <description>The time for half of the ingested solids to leave the stomach. Following a meal consisting of two eggs labeled with technetium Tc 99m sulfur colloid (1 mCi) served with 50g of Canadian bacon and one slice of bread gastric emptying of solids was assessed with scintigraphy imaging.</description>
        <time_frame>post-treatment, approximately 14-17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying of Solids (T1/2)</title>
          <description>The time for half of the ingested solids to leave the stomach. Following a meal consisting of two eggs labeled with technetium Tc 99m sulfur colloid (1 mCi) served with 50g of Canadian bacon and one slice of bread gastric emptying of solids was assessed with scintigraphy imaging.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.5" lower_limit="142.7" upper_limit="215.4"/>
                    <measurement group_id="O2" value="172.3" lower_limit="135.3" upper_limit="180.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Change in subject's weight, in kilograms</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change in subject's weight, in kilograms</description>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="85.7" upper_limit="105.4"/>
                    <measurement group_id="O2" value="101.9" lower_limit="85.6" upper_limit="114.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>Change in subjects BMI, in kilograms per meter squared.</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <description>Change in subjects BMI, in kilograms per meter squared.</description>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" lower_limit="29" upper_limit="38.5"/>
                    <measurement group_id="O2" value="32.3" lower_limit="30.1" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FGF-19</title>
        <description>Change in fasting fibroblast growth factor (FGF)-19 expression.</description>
        <time_frame>baseline, post-treatment approximately 14 - 17 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FGF-19</title>
          <description>Change in fasting fibroblast growth factor (FGF)-19 expression.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="33.8" upper_limit="100"/>
                    <measurement group_id="O2" value="90.2" lower_limit="56.8" upper_limit="143.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the subject's participation in the study, approximately five weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ursodiol</title>
          <description>Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
Ursodiol</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo capsules to be taken twice daily
Ursodiol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Camilleri</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2687</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

